×
Zoetis Cash on Hand 2011-2024 | ZTS
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Zoetis cash on hand for the quarter ending June 30, 2024 was
$1.574B
, a
8.33% decline
year-over-year.
Zoetis cash on hand for 2023 was
$2.041B
, a
43% decline
from 2022.
Zoetis cash on hand for 2022 was
$3.581B
, a
2.75% increase
from 2021.
Zoetis cash on hand for 2021 was
$3.485B
, a
3.3% decline
from 2020.
View More
Zoetis Cash on Hand 2011-2024 | ZTS
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Zoetis cash on hand for 2023 was
$2.041B
, a
43% decline
from 2022.
Zoetis cash on hand for 2022 was
$3.581B
, a
2.75% increase
from 2021.
Zoetis cash on hand for 2021 was
$3.485B
, a
3.3% decline
from 2020.
Related Stocks
Company Name
Market
Cap
Takeda Pharmaceutical (TAK)
$47.3B
Merck (MKGAF)
$23.7B
Astellas Pharma (ALPMY)
$21.5B
Summit Therapeutics (SMMT)
$19B
Sandoz Group AG (SDZNY)
$17.5B
United Therapeutics (UTHR)
$15.4B
Shionogi (SGIOY)
$13.3B
Neurocrine Biosciences (NBIX)
$12.4B
Catalent (CTLT)
$11B
Orion OYJ (ORINY)
$7.4B
Revolution Medicines (RVMD)
$7.3B
Jazz Pharmaceuticals (JAZZ)
$6.9B
Ionis Pharmaceuticals (IONS)
$6.1B
Hikma Pharmaceuticals Plc (HKMPF)
$5.7B
Madrigal Pharmaceuticals (MDGL)
$5.1B
Crinetics Pharmaceuticals (CRNX)
$4.2B
Corcept Therapeutics (CORT)
$4.1B
Dyne Therapeutics (DYN)
$3.5B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.7B
PTC Therapeutics (PTCT)
$2.7B
Arrowhead Pharmaceuticals (ARWR)
$2.5B
Catalyst Pharmaceuticals (CPRX)
$2.4B
Soleno Therapeutics (SLNO)
$2.1B
Recursion Pharmaceuticals (RXRX)
$1.9B
Centessa Pharmaceuticals (CNTA)
$1.8B
Xencor (XNCR)
$1.6B
BioCryst Pharmaceuticals (BCRX)
$1.6B
Harrow (HROW)
$1.5B
Cassava Sciences (SAVA)
$1.5B
Ardelyx (ARDX)
$1.4B